Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 215 of 6351
-
New T-Cell therapy aims to fight Hard-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for Tough-to-Treat multiple myeloma: CM336 enters phase 3 trial
Disease control Not yet recruitingThe purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Phase 3 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:47 UTC
-
Freeze, then boost: novel combo could spare bladders from removal
Disease control Recruiting nowProfessional Translation: This study is a single-center, prospective, non-randomized, parallel-controlled clinical trial initiated and conducted by the Department of Urology at the First Affiliated Hospital of Naval Medical University. The Principal Investigator is Professor Zha…
Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can an immunotherapy combo boost cervical cancer treatment?
Disease control Recruiting nowThe objective of this clinical trial is to investigate the efficacy and safety of Enlonstobart combined with concurrent chemoradiotherapy following induction chemotherapy for locally advanced cervical cancer. The primary questions it aims to address are: Can the Enlonstobart com…
Phase 4 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Promising new combo tackles tough leukemia
Disease control Recruiting nowETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone reg…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 26, 2026 15:21 UTC
-
Can a fitness app boost recovery after heart valve replacement?
Disease control Recruiting nowThis trial evaluates the effectiveness of CardioHeartConnect, an eight-week mobile cardiac rehabilitation intervention using Peloton fitness modules, compared to educational control among patients recovering from transcatheter aortic valve replacement (TAVR). The study aims to im…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial launches
Disease control Recruiting nowThis is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a l…
Phase 3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a drug duo outsmart a rare skin cancer?
Disease control Recruiting nowThis is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma. The primary endpoint of the phase I study was to determine the recommende…
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New CAR T-Cell therapy aims to stop High-Risk leukemia from returning
Disease control Recruiting nowThe goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control Recruiting nowThis study is A Randomized, Active-Controlled, Open-Label National Multicenter Phase 2 Registration Clinical Study of Yttrium \[90Y\] Microsphere Injection in Combination with Camrelizumab and/or Apatinib and Yttrium \[90Y\] Microsphere Injection Alone versus Conventional Transca…
Phase 2 • Sponsor: GrandPharma (China) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a Botox-Like shot stop chronic migraines? big trial underway
Disease control Recruiting nowIn this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include…
Phase 3 • Sponsor: Merz Therapeutics GmbH • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to stop blood cancer relapse after transplant
Disease control Recruiting nowThis is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of venetoclax-enhanced BUCY (Ven-BUCY) conditioning compared to the standard BUCY regimen in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndro…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer?
Disease control Recruiting nowPM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.
Phase 2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can an experimental antibody boost chemo's power against lymphoma?
Disease control OngoingTo evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a daily pill slow the wobble of spinocerebellar degeneration?
Disease control OngoingThis is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening pe…
Phase 3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug duo aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be …
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Drug duo aims to tackle tough lung cancers after first treatment fails
Disease control OngoingThe goal of this clinical trial is to evaluate whether sacituzumab govitecan (TROP2 antibody-drug conjugate) in combination with anlotinib (multi-target tyrosine kinase inhibitor) can improve treatment efficacy and safety in patients with driver gene-negative locally advanced or …
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New targeted drug combo aims to fight rare lymphoma
Disease control Recruiting nowA Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype
Phase 3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:20 UTC
-
Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
Disease control Recruiting nowThe study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a targeted radiation boost improve prostate cancer control?
Disease control Recruiting nowHYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized intermediate- or high-risk prostate cancer. Definitive radi…
Sponsor: Regina Elena Cancer Institute • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC